NO20042013L - Fremgangsmate for behandling av depresjon og andre CNS forstyrrelser ved anvendelse av enantiomerikalsk anriket desmethyl-og didesmenthyl-metabolitter av citalopram - Google Patents

Fremgangsmate for behandling av depresjon og andre CNS forstyrrelser ved anvendelse av enantiomerikalsk anriket desmethyl-og didesmenthyl-metabolitter av citalopram

Info

Publication number
NO20042013L
NO20042013L NO20042013A NO20042013A NO20042013L NO 20042013 L NO20042013 L NO 20042013L NO 20042013 A NO20042013 A NO 20042013A NO 20042013 A NO20042013 A NO 20042013A NO 20042013 L NO20042013 L NO 20042013L
Authority
NO
Norway
Prior art keywords
didesmenthyl
desmethyl
citalopram
metabolites
depression
Prior art date
Application number
NO20042013A
Other languages
English (en)
Inventor
Larry R Bush
Mark G Currie
Chris H Senanayake
Kevin Q Fang
Original Assignee
Sepracor Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sepracor Inc filed Critical Sepracor Inc
Publication of NO20042013L publication Critical patent/NO20042013L/no

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D307/00—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom
    • C07D307/77—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom ortho- or peri-condensed with carbocyclic rings or ring systems
    • C07D307/87—Benzo [c] furans; Hydrogenated benzo [c] furans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/10—Drugs for genital or sexual disorders; Contraceptives for impotence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/02—Muscle relaxants, e.g. for tetanus or cramps
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/26—Psychostimulants, e.g. nicotine, cocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/34—Tobacco-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/14—Vasoprotectives; Antihaemorrhoidals; Drugs for varicose therapy; Capillary stabilisers
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D317/00—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms
    • C07D317/08—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms having the hetero atoms in positions 1 and 3
    • C07D317/10—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms having the hetero atoms in positions 1 and 3 not condensed with other rings
    • C07D317/14—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms having the hetero atoms in positions 1 and 3 not condensed with other rings with substituted hydrocarbon radicals attached to ring carbon atoms
    • C07D317/18—Radicals substituted by singly bound oxygen or sulfur atoms
    • C07D317/20—Free hydroxyl or mercaptan

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Psychiatry (AREA)
  • Pain & Pain Management (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Addiction (AREA)
  • Endocrinology (AREA)
  • Hospice & Palliative Care (AREA)
  • Diabetes (AREA)
  • Reproductive Health (AREA)
  • Vascular Medicine (AREA)
  • Hematology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Anesthesiology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Gynecology & Obstetrics (AREA)
  • Obesity (AREA)
  • Urology & Nephrology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
NO20042013A 2001-11-08 2004-05-14 Fremgangsmate for behandling av depresjon og andre CNS forstyrrelser ved anvendelse av enantiomerikalsk anriket desmethyl-og didesmenthyl-metabolitter av citalopram NO20042013L (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US33760801P 2001-11-08 2001-11-08
PCT/US2002/035408 WO2003040121A1 (en) 2001-11-08 2002-11-05 Methods for treating depression and other cns disorders using enantiomerically enriched desmethyl- and didesmethyl-metabolites of citalopram

Publications (1)

Publication Number Publication Date
NO20042013L true NO20042013L (no) 2004-05-14

Family

ID=23321236

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20042013A NO20042013L (no) 2001-11-08 2004-05-14 Fremgangsmate for behandling av depresjon og andre CNS forstyrrelser ved anvendelse av enantiomerikalsk anriket desmethyl-og didesmenthyl-metabolitter av citalopram

Country Status (17)

Country Link
US (1) US20040266864A1 (no)
EP (1) EP1446396A1 (no)
JP (1) JP2005510518A (no)
KR (1) KR20050043776A (no)
CN (1) CN1705654A (no)
AU (1) AU2002356903A2 (no)
BR (1) BR0213949A (no)
CA (1) CA2465186A1 (no)
HU (1) HUP0401934A3 (no)
IL (1) IL161617A0 (no)
MX (1) MXPA04004368A (no)
NO (1) NO20042013L (no)
NZ (1) NZ532478A (no)
PL (1) PL368452A1 (no)
RU (1) RU2004117211A (no)
WO (1) WO2003040121A1 (no)
ZA (1) ZA200403409B (no)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2408368C2 (ru) 2005-06-27 2011-01-10 Биовэйл Лэборэториз Интернэшнл С.Р.Л. Препараты соли бупропиона с модифицированным высвобождением
US20070049626A1 (en) * 2005-08-26 2007-03-01 Tran Pierre V Treating premature ejaculation using gabapentin and pregabalin prodrugs
BRPI0720252A2 (pt) * 2006-12-08 2014-01-07 Xenoport Inc Uso de pró-fármacos de análogos de gaba para tratar doenças
KR101103118B1 (ko) * 2007-11-02 2012-01-04 동아제약주식회사 신규한 1,3-디히드로-5-이소벤조퓨란카르보니트릴 유도체 화합물 및 이를 함유하는 조루증 치료용 약학조성물
US9056850B2 (en) * 2008-10-17 2015-06-16 Janssen Pharmaceutica N.V. Process for the preparation of compounds useful as inhibitors of SGLT
RU2488390C2 (ru) * 2008-12-29 2013-07-27 Тартуский Университет Ингибиторы аргиназы для лечения депрессии
US20110009347A1 (en) 2009-07-08 2011-01-13 Yin Liang Combination therapy for the treatment of diabetes
SG10201500258WA (en) 2009-10-14 2015-03-30 Janssen Pharmaceutica Nv Process for the preparation of compounds useful as inhibitors of sglt2
EP2377522B1 (en) * 2010-04-15 2013-01-16 Sanovel Ilaç Sanayi Ve Ticaret Anonim Sirketi Orally disintegrating tablet formulations of mirtazapine and process for preparing the same
LT2568988T (lt) 2010-05-11 2016-09-12 Janssen Pharmaceutica, N.V. Farmacinės kompozicijos, apimančios 1-(beta-d-gliukopiranozil)-2-tienilmetilbenzeno darinius kaip sglt inhibitorius
RU2436782C1 (ru) * 2010-06-10 2011-12-20 Новосибирский институт органической химии им. Н.Н. Ворожцова Сибирского отделения Российской академии наук (НИОХ СО РАН) 2-МЕТОКСИ-4[(3aR,7aS)-3,3,6-ТРИМЕТИЛ-1,3,3a,4,5,7a-ГЕКСАГИДРО-2-БЕНЗОФУРАН-1-ИЛ]ФЕНОЛ - НОВОЕ СРЕДСТВО ДЛЯ ЛЕЧЕНИЯ БОЛЕЗНИ ПАРКИНСОНА
AU2012241897C1 (en) 2011-04-13 2017-05-11 Janssen Pharmaceutica Nv Process for the preparation of compounds useful as inhibitors of SGLT2
KR101427221B1 (ko) * 2012-08-29 2014-08-13 주식회사 에스텍파마 플루복사민 자유 염기의 정제방법 및 이를 이용한 고순도 플루복사민 말레이트의 제조방법
AU2016219253C1 (en) * 2015-02-11 2022-12-08 Pgi Drug Discovery Llc 1-heterocyclyl isochromanyl compounds and analogs for treating CNS disorders
WO2024223797A1 (en) 2023-04-28 2024-10-31 Institut National de la Santé et de la Recherche Médicale Use of cyp3a4 inhibitors for the treatment of hepatitis d virus (hdv) infections

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NL1017415C1 (nl) * 2000-02-24 2001-05-18 Lundbeck & Co As H Werkwijze voor de bereiding van Citalopram.
NL1017417C1 (nl) * 2000-03-03 2001-03-16 Lundbeck & Co As H Werkwijze voor de bereiding van Citalopram.
CZ20023100A3 (cs) * 2000-03-13 2003-02-12 H. Lundbeck A/S Způsob výroby citalopramu
JP3798982B2 (ja) * 2000-12-22 2006-07-19 ハー・ルンドベック・アクチエゼルスカベット 純粋なシタロプラムの製造方法

Also Published As

Publication number Publication date
US20040266864A1 (en) 2004-12-30
PL368452A1 (en) 2005-03-21
WO2003040121A1 (en) 2003-05-15
KR20050043776A (ko) 2005-05-11
RU2004117211A (ru) 2005-03-27
JP2005510518A (ja) 2005-04-21
HUP0401934A2 (hu) 2005-01-28
IL161617A0 (en) 2004-09-27
MXPA04004368A (es) 2004-08-11
EP1446396A1 (en) 2004-08-18
NZ532478A (en) 2007-02-23
ZA200403409B (en) 2005-10-26
CN1705654A (zh) 2005-12-07
AU2002356903A2 (en) 2003-05-19
CA2465186A1 (en) 2003-05-15
BR0213949A (pt) 2004-08-31
HUP0401934A3 (en) 2007-05-29

Similar Documents

Publication Publication Date Title
NO20034996D0 (no) Nye arylsusfonamidforbindelser for behandlingen av fedme, type II diabetesog CNS-forstyrrelser
NO20014047D0 (no) Monoamin reopptaksinhibitorer for behandling av CNS forstyrrelser
EP1443929A4 (en) TREATMENT OF CNS DISTURBANCES WITH CNS TARGET MODULATORS
NO20035162D0 (no) Fremgangsmåte for fremstilling av prostaglandiner og analoger derav
NO20043085L (no) Fremgangsmater og sammensetninger for behandling av forstyrrelser i sentralnervesystemet
NO20023928D0 (no) Fremgangsmåte ved fremstillingen av citalopram
NO20011271A (no) Fremgangsmåte for fremstilling av ren citalopram
NO20041386L (no) Kombinasjoner for bahandling av immunoinflammatoriske forstyrrelser
NO20024007L (no) Fremgangsmåte ved fremstillingen av citalopram
NO20013943D0 (no) Fremgangsmate for fremstilling av Citalopram
NO20040027L (no) Fremgangsmate for fremstillingen av escitalopram
NO20034538L (no) Anvendelsen av enantiomer ren escitalopram
ZA200403409B (en) Methods for treating depression and other CNS disorders using enantiomerically enriched desmethyl- and didesmethyl-metabolites of citalopram.
DK1383733T3 (da) Fremgangsmåde til fremstilling af 1,3-substituerede indener og aryl-sammenföjede azapolycykliske forbindelser
NO20041200L (no) Fremgangsmate for fremstilling av citalopram.
ID30430A (id) Senyawa-senyawa dan metode-metode untuk pengobatan gangguan-gangguan asma, alergi dan inflamasi
NO20006296L (no) Fremgangsmåte til fremstilling av trykkfilt og trykkfilt
NO20024180L (no) Fremgangsmåte ved fremstillingen av citalopram
NO20031413D0 (no) Ny fremgangsmåte for fremstilling av oksabispidiner
NO20024213L (no) FremgangsmÕte ved fremstilling av citalopram
NO20025423L (no) Fremgangsmate for fremstilling av Citalopram
DK1039888T3 (da) Fremgangsmåde til forøgelse af produktionen og forbedring af kvaliteten af sæd
NO20032156D0 (no) Behandling av angstforstyrrelser
NO990450D0 (no) Behandling av sinnslidelser
NO972114D0 (no) Fremgangsmåte for behandling av H2S-holdige gass-strömmer

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application